Weight loss has always been big business, but it’s exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs.
In the first half of 2023, sales of Ozempic and Wegovy rose by 58% and 363%, respectively. That’s after quarterly prescriptions for those types of GLP-1 treatments, which mimic a hormone in the gut to suppress a person’s appetite, increased 300% between early 2020 and the end of last year.
But as consumers and businesses pour more money and resources into tackling the obesity epidemic, which costs the U.S. more than $170 billion a year, drug developers aren’t alone in coming up with innovative solutions.
Signos, a five-year-old startup, is taking an approach that doesn’t involve pills.
The company is using off-the-shelf continuous glucose monitors, or CGMs, and providing real-time diet and exercise recommendations based on an individual’s readings. CGMs are small sensors worn on the upper arm that track glucose levels, primarily for people with diabetes. The information is wirelessly sent to a smartphone, allowing the user to better prevent emergencies.
Signos uses CGMs built by Dexcom. The startup has its own app that shows users how their body responds to specific foods, what causes their glucose to spike and when they should exercise to get the best results for weight loss.
On Tuesday, Signos said it closed a $20 million funding round led by Cheyenne Ventures and GV, formerly known as Google Ventures. Dexcom Ventures also contributed to the financing. Signos said it will use the fresh capital to continue its research into metabolic health and to expand its team, which is currently around 45 people.
“Whether you have five pounds to lose or 100, we want to make sure we’re able to help everybody,” Sharam Fouladgar-Mercer, Signos’ co-founder and CEO, told CNBC in an interview.
Customers who sign up for Signos can choose a one-month, three-month or six-month plan. With the half-year plan, users pay $143 a month, which includes all of the pricey CGMs they’ll need during that time. The company declined to share specific details about how many people are currently using its platform.
Fouladgar-Mercer said the long timelines are designed to attract users who are serious about their weight-loss journey. Additionally, the sensors themselves have a long wear time. The Dexcom G6 and G7, the latest devices, can measure glucose for up to 10 days. Signos currently supports the G6 and will soon work with the G7 as well.
Fouladgar-Mercer said Signos is using Dexcom’s CGMs as part of a clinical study approved by an institutional review board designated by the U.S. Food and Drug Administration to monitor biomedical research involving real people.
Fouladgar-Mercer said he created the company in 2018 partly because of his own struggle to manage weight throughout his life. He trained as an athlete and played hockey in college, but he said he noticed how food often affected him differently from the way it affected his teammates.
He said he always felt that, in an effort to understand an individual’s metabolism, there was a “critical component” missing, and it had been nagging at him for 30 years.
Signos helps users understand the right decision to make in the moment, but they can go “behind the scenes” and learn as much about the science as they’d like, Fouladgar-Mercer said. Users can also integrate sleep data, heart rate data, and exercise data from their Apple Watch to personalize their profile even more.
“Once they trust the system works and they understand the methodology, they can just follow the really quick, here’s what I do, here’s what I do, here’s what I do,” Fouladgar-Mercer said. “And that’s how you get behavioral change.”
Though Dexcom primarily develops its CGMs for patients with diabetes, the company is also working toward broader applications. For instance, next year it’s releasing a new product meant for people who aren’t taking insulin. Similarly, Abbott Laboratories, which dominates the global CGM market, is hoping to bring its first consumer-facing CGM, called Lingo, to the U.S. next year, adding personalized coaching with recommendations about diet, sleep and exercise.
Fouladgar-Mercer said Signos has more data points than “anybody does in the world for non-diabetics.” He added that since the company built its first product almost five years ago, it’s been able to focus on fine-tuning its technology.
“I don’t want to incorrectly set expectations,” Fouladgar-Mercer said. “I think a lot of times, it’s like, ‘Oh, lost X pounds in X days.’ That’s not what we’re trying to accomplish. It’s really, how do we put you on a sustainable journey? And that journey is not going to be done in two or three days.”
Fouladgar-Mercer said Signos can work well alongside Ozempic and Wegovy from Novo Nordisk and other GLP-1 treatments. Novo Nordisk’s share price has quadrupled since 2018, and the company is now the most valuable in Europe.
Fouladgar-Mercer said GLP-1 drugs are a “powerful tool” that can help people jump-start weight loss, but it can be challenging to keep weight off if they stop taking the medication. Platforms such as Signos can help to reinforce and maintain a healthier lifestyle over time, he said.
Ultimately, he said, he wants people to use Signos to learn how to make better choices that work best for their bodies.
Signos, Fouladgar-Mercer said, can use technology and data “to drive behavioral change, and then wrap that all in a system that really is focused on driving and solving this biggest problem we have in America, which is weight.”
OpenAI on Wednesday announced ChatGPT for Teachers, a version of its artificial intelligence chatbot that is designed for K-12 educators and school districts.
Educators can use ChatGPT for Teachers to securely work with student information, get personalized teaching support and collaborate with colleagues within their district, OpenAI said. There are also administrative controls that district leaders can use to determine how ChatGPT for Teachers will work within their communities.
OpenAI said it is initially launching ChatGPT for Teachers with a cohort of districts that represent roughly 150,000 educators. ChatGPT for Teachers will be free to K-12 educators in the U.S. through June 2027, the company said.
“Our objective here is to make sure that teachers have access to AI tools as well as a teacher-focused experience so they can truly guide AI use,” Leah Belsky, vice president of education at OpenAI, told reporters during a briefing.
The company said student data will be protected and that anything shared within ChatGPT for Teachers will not be used to train its models.
Read more CNBC tech news
OpenAI rocketed into the mainstream following the launch of its generic ChatGPT chatbot in 2022. It’s faced criticism from teachers and parents who argue that students can use the tool to cheat and avoid engaging in critical thinking.
ChatGPT for Teachers is not intended for students, but OpenAI said giving teachers hands-on experience with AI tools will help them understand and establish best practices in their classrooms.
“Every student today is growing up with AI, and teachers play a central role in helping them learn how to use these tools responsibly and effectively,” the company said in a blog post. “To support that work, educators need space to explore AI for themselves.”
In July, OpenAI released a product within ChatGPT called “study mode.” Study mode was built with college-age students in mind, and it aims to help them work through problems step-by-step before they arrive at an answer.
OpenAI said it built study mode as “a first step in a longer journey to improve learning in ChatGPT.”
Block said Wednesday that it expects gross profit to increase in the mid-teens annually for the next three years, reaching about $15.8 billion in 2028.
At the payment company’s first investor day event since 2022, Block unveiled a three-year financial outlook. The announcements land as Wall Street has turned skeptical on Block’s prospects, pushing the stock down by more than 30% in 2025, while major indexes have notched solid gains.
Block shares were initially halted around the time of the announcement and then jumped 9% when trading resumed.
The fresh guidance also comes two weeks after Block reported quarterly results, missing revenue estimates for a sixth straight time. Block has been diversifying away from its point-of-sale business, which has become increasingly crowded, launching more services tied to Cash App and offering artificial intelligence tools to sellers.
Block said in its new outlook that adjusted operating income is projected to increase about 30% annually, topping $4.6 billion by 2028. Adjusted earnings per share will grow in the low 30% range, reaching $5.50 in three years.
Chief Financial Officer Amrita Ahuja told CNBC ahead of the release that the company is entering a new phase of execution.
Stock Chart IconStock chart icon
Block vs. Nasdaq this year
“Since 2022, our last investor day, we’re nearly double the size from a gross profit perspective,” Ahuja said, adding that earnings before interest, taxes, depreciation and amortization “more than tripled.”
Block also introduced a new non-GAAP cash flow metric, designed to reflect the capital required to grow its lending products, which it expects to reach more than $4 billion, or 25% of gross profit, by 2028.
For 2026, Block expects gross profit to rise 17% to $11.98 billion, with adjusted operating income and EPS both increasing more than 30%, to $2.7 billion and $3.20, respectively.
Ahuja said Block has adopted a “rule of 40” investment framework. That typically refers to revenue growth rate plus profit margin exceeding 40. She said the company expects to reach that metric this year and has reorganized around a single roadmap with a shared technical infrastructure.
“That transformation has resulted in us moving faster, with more connected decisions across our ecosystem,” Ahuja said.
On Wednesday, Block also expanded its share repurchase program by $5 billion, adding to the $1.1 billion in remaining authorization as of Sept. 30. The prior buyback plan was for up to $4 billion in purchases.
Block CEO Jack Dorsey, who co-founded the company as Square in 2009, was in attendance at the investor event. Dorsey has largely been out of public view in recent years.
Kraken is one of the world’s largest crypto exchanges.
Tiffany Hagler-Geard | Bloomberg via Getty Images
Kraken confidentially filed to go public in the U.S., a person familiar with the matter told CNBC on Wednesday.
A Kraken spokesperson declined to comment on the timing of its plans.
Kraken is the latest crypto company to attempt to tap the public market since President Donald Trump came back to the White House. Crypto trading platforms Bullish and Gemini Space Station listed their shares on major stock exchanges in August and September, respectively. And in June, stablecoin issuer Circle raised just north of $1 billion in its blockbuster IPO.
Founded in 2011, Kraken is a U.S.-based platform that facilitates the trading of digital assets like bitcoin and ether. It also offers tokenized equities trading to clients in the European Union.
Kraken recently raised $800 million at a $20 billion valuation, including $200 million from Citadel Securities, the company said Tuesday in a statement. The firm plans to use those funds to expand its footprint in foreign markets, in addition to building out its payment services.